NASDAQ:RLMD Relmada Therapeutics (RLMD) News Today $3.00 +0.06 (+2.04%) (As of 03:26 PM ET) Add Compare Share Share Today's Range$2.92▼$3.0250-Day Range$2.48▼$3.7952-Week Range$1.81▼$38.68Volume79,607 shsAverage Volume216,201 shsMarket Capitalization$90.30 millionP/E RatioN/ADividend YieldN/APrice Target$10.80 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHere's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situationfinance.yahoo.com - September 26 at 7:13 AMRelmada (RLMD) Up on Positive Data for Anti-Depressant Candidatefinance.yahoo.com - September 21 at 5:37 PMRelmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Studybenzinga.com - September 20 at 1:52 PMRelmada Therapeutics Shares Rise 18% After Positive Trial Data for REL-1017marketwatch.com - September 20 at 10:35 AMRelmada Therapeutics: Long-term Study With REL-1017 Shows Rapid, Sustained Therapeutic Effectsmarkets.businessinsider.com - September 20 at 8:51 AMRelmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorderfinance.yahoo.com - September 20 at 8:51 AMRelmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readoutmsn.com - September 1 at 9:03 PMMizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)markets.businessinsider.com - August 23 at 6:51 PMFollowing a 88% decline over last year, recent gains may please Relmada Therapeutics, Inc. (NASDAQ:RLMD) institutional ownersfinance.yahoo.com - August 16 at 6:49 AMRelmada Therapeutics (RLMD) Gets a Buy from Mizuho Securitiesmarkets.businessinsider.com - August 9 at 4:33 PMRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Resultsfinanznachrichten.de - August 9 at 9:44 AMRelmada Therapeutics (NASDAQ: RLMD)fool.com - June 21 at 11:42 PMRelmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conferencefinance.yahoo.com - June 8 at 10:24 AMROSEN, RESPECTED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMDbenzinga.com - June 3 at 2:10 PMRelmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conferencefinance.yahoo.com - June 2 at 8:56 AMRelmada Therapeutics Insider Ups Holding By 62% During Yearfinance.yahoo.com - May 24 at 10:51 AMRelmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meetingfinance.yahoo.com - May 24 at 8:13 AMRelmada Therapeutics Insider Ups Holding By 62% During Year \finance.yahoo.com - May 24 at 8:13 AMSVB Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)markets.businessinsider.com - May 15 at 4:25 PMRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Resultsfinanznachrichten.de - May 12 at 4:00 AMMizuho Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)markets.businessinsider.com - May 11 at 10:59 PMRelmada Therapeutics: Q1 Earnings Insightsmsn.com - May 11 at 8:35 PMRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 11 at 5:59 PMEarnings Preview For Relmada Therapeuticsbenzinga.com - May 10 at 3:16 PMRLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.marketwatch.com - May 9 at 11:03 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMDbenzinga.com - May 8 at 7:19 PMRLMD ALERT: The Law Offices of Vincent Wong Investigate Relmada Therapeutics, Inc. for Potential Violations of Securities Lawsmarketwatch.com - May 8 at 12:00 PMRelmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023finance.yahoo.com - May 8 at 8:57 AMRLMD FRAUD ALERT: Jakubowitz Law is Investigating Relmada Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Lawsmarketwatch.com - May 5 at 10:47 AMUnusual Put Option Trade in Relmada Therapeutics (RLMD) Worth $75.00Kmsn.com - May 4 at 9:35 PMWill Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely?finance.yahoo.com - April 12 at 3:26 PMSVB Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)markets.businessinsider.com - March 28 at 7:35 AMQ4 2022 Relmada Therapeutics Inc Earnings Callfinance.yahoo.com - March 24 at 10:01 AMRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Resultsfinanznachrichten.de - March 24 at 7:35 AMRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Resultsfinance.yahoo.com - March 23 at 6:44 PMPreview: Relmada Therapeutics's Earningsbenzinga.com - March 22 at 2:36 PMRelmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023finance.yahoo.com - March 17 at 9:47 AMRelmada Therapeutics, Inc. (NASDAQ:RLMD) is favoured by institutional owners who hold 52% of the companyfinance.yahoo.com - February 17 at 7:56 AMRelmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Hold" by Brokeragesmarketbeat.com - February 17 at 4:20 AMDeep Track Capital Now Owns 9.43% of Relmada Therapeutics (RLMD)nasdaq.com - February 16 at 11:48 PMShort Interest in Relmada Therapeutics, Inc. (NASDAQ:RLMD) Decreases By 20.4%marketbeat.com - February 13 at 4:42 AMSVB Securities Keeps Their Buy Rating on Relmada Therapeutics (RLMD)markets.businessinsider.com - January 23 at 9:56 AMRelmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officerfinance.yahoo.com - January 9 at 9:56 AMSergio Traversa Is The CEO & Director of Relmada Therapeutics, Inc. (NASDAQ:RLMD) And They Just Picked Up 62% More Sharesfinance.yahoo.com - December 15 at 9:16 AMInsider Buying: Relmada Therapeutics, Inc. (NASDAQ:RLMD) CEO Buys 55,250 Shares of Stockmarketbeat.com - December 12 at 9:24 PMLooking Into Relmada Therapeutics's Recent Short Interestmsn.com - December 9 at 12:50 PMRelmada Therapeutics Shares Plumb New Depths After Lead Program Setback >RLMDmarketwatch.com - December 8 at 3:26 PMRelmada Therapeutics Shares Slide Premarket on Study Failure >RLMDmarketwatch.com - December 8 at 10:26 AMRelmada Shares Nosedive As Another Depression Trial Goes Up In Smokefinance.yahoo.com - December 8 at 10:26 AMRelmada Therapeutics shares decline 40% on Thursdayfinance.yahoo.com - December 8 at 10:26 AM Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Media Mentions By Week RLMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLMD News Sentiment▼0.620.68▲Average Medical News Sentiment RLMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLMD Articles This Week▼21▲RLMD Articles Average Week Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Anebulo Pharmaceuticals News Ocuphire Pharma News DURECT News Syros Pharmaceuticals News LifeVantage News Immunome News Kezar Life Sciences News Shattuck Labs News Incannex Healthcare News Nkarta News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:RLMD) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.